Bayer to spend up to $4bn on Asklepios BioPharmaceutical
27-10-2020
photobyphm / Shutterstock.com
Takeda subsidiary Baxalta has agreed to drop its fightback against a $173 million award in favour of Bayer after an appeals court upheld a patent infringement win for the German conglomerate.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Takeda, Bayer, Adynovate, Nektar Therapeutics, Federal Circuit, patent infringement haemophilia A
